About pacira biosciences inc - PCRX
Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
PCRX At a Glance
Pacira Biosciences, Inc.
5401 West Kennedy Boulevard
Tampa, Florida 33609
| Phone | 1-813-553-6680 | Revenue | 726.41M | |
| Industry | Pharmaceuticals: Major | Net Income | 7.03M | |
| Sector | Health Technology | 2025 Sales Growth | 3.63% | |
| Fiscal Year-end | 12 / 2026 | Employees | 829 | |
| View SEC Filings |
PCRX Valuation
| P/E Current | 148.528 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 165.685 |
| Price to Sales Ratio | 1.605 |
| Price to Book Ratio | 1.535 |
| Price to Cash Flow Ratio | 7.67 |
| Enterprise Value to EBITDA | 11.294 |
| Enterprise Value to Sales | 1.852 |
| Total Debt to Enterprise Value | 0.311 |
PCRX Efficiency
| Revenue/Employee | 876,249.698 |
| Income Per Employee | 8,484.922 |
| Receivables Turnover | 5.841 |
| Total Asset Turnover | 0.515 |
PCRX Liquidity
| Current Ratio | 4.544 |
| Quick Ratio | 3.276 |
| Cash Ratio | 1.977 |
PCRX Profitability
| Gross Margin | 71.499 |
| Operating Margin | 3.869 |
| Pretax Margin | 2.323 |
| Net Margin | 0.968 |
| Return on Assets | 0.499 |
| Return on Equity | 0.956 |
| Return on Total Capital | 0.633 |
| Return on Invested Capital | 0.61 |
PCRX Capital Structure
| Total Debt to Total Equity | 60.337 |
| Total Debt to Total Capital | 37.631 |
| Total Debt to Total Assets | 33.062 |
| Long-Term Debt to Equity | 58.918 |
| Long-Term Debt to Total Capital | 36.746 |